In recent trading session, Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) saw 1.69 million shares changing hands at last check today with its beta currently measuring 0.56. Company’s recent per share price level of $0.25 trading at $0.02 or 8.30% at last check today assigns it a market valuation of $51.42M. That most recent trading price of CYCC’s stock is at a discount of -1500.0% from its 52-week high price of $4.00 and is indicating a premium of 32.0% from its 52-week low price of $0.17. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.16 million shares which gives us an average trading volume of 290.75K if we extend that period to 3-months.
For Cyclacel Pharmaceuticals Inc (CYCC), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 3.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) trade information
Upright in the green today for gaining 8.30%, in the last five days CYCC remained trading in the green while hitting it’s week-highest on Friday, 04/25/25 when the stock touched $0.25 price level, adding 1.65% to its value on the day. Cyclacel Pharmaceuticals Inc’s shares saw a change of -34.04% in year-to-date performance and have moved 9.69% in past 5-day. Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) showed a performance of -18.53% in past 30-days. Number of shares sold short was 55680.0 shares which calculate 0.25 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 1 to the stock, which implies a rise of 75.0% to its recent value today. Analysts have been projecting 1 as a low price target for the stock while placing it at a high target of 1. It follows that stock’s current price would drop -300.0% in reaching the projected high whereas dropping to the targeted low would mean a loss of -300.0% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 57.31% during past 5 years.
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)’s Major holders
Insiders are in possession of 93.93% of company’s total shares while institution are holding 0.35 percent of that, with stock having share float percentage of 5.78%. Investors also watch the number of corporate investors in a company very closely, which is 0.35% institutions for Cyclacel Pharmaceuticals Inc that are currently holding shares of the company.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 5.8 shares of worth $1546.0 or 0.00% of the total outstanding shares. The later fund manager was in possession of 8.96 shares on Feb 28, 2025 , making its stake of worth around $2390.0 in the company or a holder of 0.00% of company’s stock.
